Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA

FSNUY - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$133.37B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Fresenius SE & Co. KGaAFresenius SE & Co. KGaA19.21.96%8%7.30.6

Earnings Call Q3 2026

November 4, 2026 - AI Summary

Q3 performance: strong earnings + cash + returns; group margin lifted - Organic revenue grew ~5%; core EPS +14% at constant currency (also strong year-to-date). - Group EBIT margin ~11% in Q3, up +50 bps YoY; group margin guidance raised to “above 11.5%” (previously lower). - Free cash flow > doubled YoY; last 12 months FCF ~EUR 1.9bn, with strong cash conversion (cash conversion >1). - Most notable “surprising/standout” metric: management claims they achieved the highest ROIC in the decade.
Full-year outlook upgraded (core EPS + interest) with FX sensitivity - Core EPS growth guidance increased to upper half of 10%–15% range at constant currency. - Interest expense expected < EUR 300m for full year (benefiting from lower debt/refinancing). - If FX stays at spot rates (30 Sept), they expect no material impact on reported revenue/EBIT/net income.
Kabi (largest value driver): innovation-led growth vectors scaling; quality focus continues - Kabi organic revenue +6% (upper half of structural growth band). - Growth vectors +9%; biopharma +29% organic growth (Tyenne plus denosumab demand), while MedTech (Ivenix) continues to accelerate. - Biopharma profitability: record Q3 margins, reaching a level around management’s 2030 ambition (but not treated as a sustainable quarterly run-rate—R&D ramp likely ahead). - Quality risk / remediation—Melrose Park (FDA): facility “fully operational,” no patient safety concerns; management expects no material impact on 2026 production/supply/financials (mitigation ongoing).

Exclusive for Stockcircle Pro members

Sign upSign Up
$0.84

Current Fair Value

94.2% downside

Overvalued by 94.2% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$133.37 Billion
Enterprise Value$143.68 Billion
Annual dividend$0.30
Dividend yield1.96%
Earnings per Share$0.14
Beta0.83
Outstanding Shares8,955,272,000

Return

Return on Equity7.75%ROE
Return on Assets3.76%
Return on Invested Capital7.12%

Valuation & Multiples

P/E Ratio19.15P/E Ratio
PEG114.5PEG
Price to Sales7.34Price to Sales
Price to Book Ratio7.34Price to Book Ratio
Enterprise Value to Revenue6.03
Enterprise Value to EBIT59.08
Enterprise Value to Net Income90
Total Debt to Enterprise0.08
Debt to Equity0.59Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 4, 2026
EPS
$0.25
Est. $0.22
Revenue
$6.52 B
Est. $6.51 B

Next Earnings Call

Expected Date
February 24, 2027
EPS Estimate
$0.26
Consensus analyst estimate
Revenue Estimate
$6.98 B
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Fresenius SE & Co. KGaA

178,486 employees
CEO: Michael Sen

Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured ...